Teva Pharmaceutical Industries Investor Presentation — November 2020

Document content

Teva Pharmaceutical Industries Ltd.

Third Quarter 2020 Results

November 5, 2020Cautionary Note Regarding Forward- Looking Statements

This presentation contains forw ard- looking statements w ithin the meaning of the Private Securities Litigation Reform Act of 1995, w hich are based on management ’s current beliefs and expectations and are subject to

substantial risks and uncertainties, both know n and unknow n, that could cause our future results, performance or achievements todiffer significantly from that expressed or implied by such forw ard- looking statements.

Important factors that could cause or contribute to such differences include risks relating to:

•our ability to successfully compete in the marketplace, including: that w e are substantially dependent on our generic products; c onsolidation of our customer base and commercial alliances among our customers; the

increase in the number of competitors targeting generic opportunities and seeking U.S. market exclusivity for generic versions o f significant products; competition for our specialty products, especially COPAXONE®, our

leading medicine, w hich faces competition from existing and potential additional generic versions, competing glatiramer acetate products and orally -administered alternatives; the uncertainty of commercial success of

AJOVY®or A USTEDO®; competition from companies w ith greater resources and capabilities; delays in launches of new products and our ability to achi eve expected results from investments in our product pipeline; ability

to develop and commercialize biopharmaceutical products; efforts of pharmaceutical companies to limit the use of generics, inclu ding through legislation and regulations and the effectiveness of our patents and other

measures to protect our intellectual property rights;

•our substantial indebtedness, w hich may limit our ability to incur additional indebtedness, engage in additional transactions or make new investments, may result in a further dow ngrade of our credit ratings; and our

inability to raise debt or borrow funds in amounts or on terms that are favorable to us;

•our business and operations in general, including: uncertainty regarding the magnitude, duration, and geographic reach of the COV ID-19 pandemic and its impact on our business, financial condition, operations, cash

flow s, and liquidity and on the economy in general; our ability to successfully execute and maintain the activities and effor ts related to the measures w e have taken or may take in response to the COVID -19 pandemic and

associated costs therew ith; effectiveness of our restructuring plan announced in December 2017; our ability to attract, hire and retain highly skilled personnel; our ability to develop and commercialize additional